Vision
To advance the development and utilization of safe and efficacious medicines through the application of Quantitative Systems Pharmacology (QSP)
- Advance the science of QSP by fostering a community for the exchange of ideas and knowledge
- Promote the application of QSP in drug development and regulatory decision-making
- Develop and maintain information resources for its members, including establishment of “best practices” for QSP approaches
- Facilitate communication and advance knowledge through sponsored sessions at professional meetings, white papers, discussion groups, and publications
QSP SIG Leadership Team
|
Dr. Friedrich is the Chief Engineer at Rosa & Co, a drug development advisory firm that specializes in mechanistic QSP modeling. She holds BS degrees in Mathematics and Engineering Systems and Computation from MIT and a PhD in Management Science and Engineering from Stanford University. Dr. Friedrich has over 18 years of experience in developing and applying mathematical models of biological systems to support development of pharmaceuticals and consumer products. Her therapeutic area experience includes diabetes, blood disorders, CNS disorders, oncology/immuno-oncology, respiratory diseases, skin diseases, auto-immune diseases, and other immune system dysfunctions and inflammatory processes. Dr. Friedrich has a long-standing interest in advancing methodologies and applications for the effective use of mechanistic QSP models. While at Rosa, Dr. Friedrich developed and published the Model Qualification Method, a systematic qualification framework for mechanistic mathematical QSP models. In her previous role at Entelos, Dr. Friedrich spearheaded development of modeling methodologies and contributed to foundational mechanistic modeling patents, including on the use of virtual patients and virtual populations to explore biological variability and uncertainty, and on the use of mechanistic models in the identification of biomarkers. |
|
Dr. Benjamin Ribba holds a Master degree and PhD in applied mathematics. He started his career in 2001 as a fellow of a European Research Grant dedicated to application of mathematics to biology and medicine. He was successively researcher in computer science at Inria from 2008 to 2015 in France where he focused his research on the development and application of mathematical models to address questions around optimization of the efficacy and delivery of anti-cancer drugs in patients. In 2015, he joined Roche Pharma Research and Early Development. He is the author of ca. 50 publications in peer-reviewed scientific journals. |
|
Dr.Ioannis (Yannis) P. Androulakis is a Professor in the Department of Biomedical Engineering, the Department of Chemical & Biochemical Engineering, and holds an Adjunct faculty position in the Department of Surgery at the Rutgers – Robert Wood Johnson Medical School. He has a BS degree from NTUA, Athens, Greece; MS/Ph.D. from Purdue University, all in Chemical Engineering followed by postdoctoral training at Princeton University. Before joining Rutgers, he was with ExxonMobil’s Corporate Strategic Research Laboratories in NJ for several years, where he eventually became a technical program leader. His research focuses on quantitative systems biology and pharmacology of inflammation, emphasizing the interactions between the circadian, endocrine, and immune systems. He is a Fellow of the American Institute for Medical and Biological Engineering and a Fellow of the American Institute of Chemical Engineers. |
|
Dr. Jingxian (JC) Chen is a senior scientist in Pharmacometrics within Quantitative Pharmacology and Pharmacometrics at Merck. Her work focuses on using population PK/PD modeling, mechanistic modeling and QSP modeling to facilitate drug development, especially for monoclonal antibody, across different therapeutics areas including metabolic disorder, infectious disease and oncology. She is currently leading the effort of QSP modeling to support Merck NASH pipeline. She received her Ph.D. degree in Pharmaceutical Sciences from School of Pharmacy, University of North Carolina at Chapel Hill with a focus on pharmacometrics. |
|
Dr. Brian J. Schmidt is a senior principal scientist in quantitative systems pharmacology within clinical pharmacology & pharmacometrics at Bristol-Myers Squibb. Brian earned his PhD in Biomedical Engineering at the University of Virginia. He received postdoctoral training in systems biology and computational biology at the University of Virginia; University of California, San Diego; and Sanford-Burnham Medical Research Institute. He also previously performed research as a dynamics engineer in QSP at Entelos, where he developed and applied mechanistic models in multiple therapeutic areas, including autoimmune, cardiovascular disease, and type 2 diabetes. He is currently leading a group responsible for the development and application of QSP platforms to support clinical development in oncology and immuno-oncology. His contributions cover multiple facets QSP, including model development, the development of new algorithms for calibrating mechanistic models to data, the development of software tools to support QSP, application of QSP to improve decision making throughout clinical development, and the application of QSP models in regulatory interactions. |
|
Dr. Yi Ting (Kayla) Lien is an associate scientist in the Clinical Pharmacology Department (Modeling and Simulation) at Genentech. She received both her BS and MS degrees in Pharmaceutical Sciences from the University at Buffalo and her Ph.D. in Pharmaceutics from the University of Florida (Center for Pharmacometrics & Systems Pharmacology). Her PhD research focuses on mechanistic PBPK/PD model on therapeutic proteins, quantitative system pharmacology modeling approach in postmenopausal osteoporosis population and optimizing dose strategies using population modeling methods. Her research findings were presented at several scientific conferences and were awarded several awards including the prestigious Quality Trainee award in the American Conference on Pharmacometrics (ACoP8) annual conference. Outside of academics, Kayla is very involved in the scientific community and have held several leadership roles such as International Society of Pharmacometric (ISoP) Student Chair, president for UF American Association of Pharmaceutical Scientists (AAPS) and American College of Clinical Pharmacology (ACCP) student chapters to assist in ensuring students/trainees’ needs are met for their career development. She has also chaired the student programming events for both ACoP8 and 9 conferences. At Genentech, she is providing modeling and simulation support to Oncology therapeutic areas. Prior to joining the Leadership team, Kayla has been an active member of the QSP ISoP SIG. |
Ioannis (Yannis) P. Androulakis (Vice-Chair)
Jingxian (JC) Chen (Communications Director)
Yi Ting (Kayla) Lien (Secretary)2021 Steering Committee Members
- Jane Bai, PhD, Office of Clinical Pharmacology, Division of Applied Regulatory Science, United States Food and Drug Administration
- John Burke, PhD, President, CEO, and Co-founder at Applied BioMath, Adjunct Faculty, Harvard Medical School
- James Gallo, PharmD, PhD, Empire State Innovation Professor, SUNY Buffalo Department of Pharmaceutical Sciences
- Rukmini Kumar, PhD, Chief Scientist and Co-founder, Vantage Research
- Tarek Leil, PhD, Group Director, Quantitative Clinical Pharmacology, BMS, Adjunct Faculty, University of Pittsburgh School of Pharmacy
- CJ Musante, PhD, Senior Scientific Director, Head of Quantitative Systems Pharmacology, Pfizer
- Mark Peterson, PhD, Senior Director, Modeling & Simulation, Vertex
- Aleksander S. Popel, Professor, Department of Biomedical Engineering, School of Medicine, Johns Hopkins University
- Saroja Ramanujan, PhD, Principal Scientist & Associate Director, Translational & Systems Pharmacology, Head of QSP, Genentech Inc.
- Matthew Riggs, PhD, Chief Science Officer, Metrum Research Group
- Julio Saez-Rodriguez, PhD, Professor of Medical Bioinformatics and Data Analysis, Heidelberg University Hospital, Group Leader, EMBL
- Stephan Schmidt, PhD, FCP, Endowed Certara Professor, University of Florida College of Pharmacy
- Birgit Schoeberl, PhD, Global Head Modeling and Simulation, PK Sciences at Novartis Institutes for BioMedical Research
- Iñaki F. Trocóniz, PhD, Professor, Universidad de Navarra, Pharmacometrics & Systems Pharmacology
- Paolo Vicini, PhD, Vice President, Development Sciences, Kymab Ltd
- Yuching Yang, PhD, Office of Clinical Pharmacology, Division of Pharmacometrics, United States Food and Drug Administration
What is Quantitative Systems Pharmacology?
The white paper below represents the NIH’s attempt to define the
opportunities and challenges facing the field of quantitative systems
pharmacology (QSP). The paper recommends the adoption of a holistic
approach to understanding the interaction of drugs with human biology.
The paper further notes that this will require the collaboration and
training of scientists from multiple disciplines, from pharmacology to
chemistry to computer science. We look forward to hearing from ideas
from our SIG members about how these disciplines can be effectively
synthesized so that QSP can continue to grow as a field.
www.nigms.nih.gov/News/reports/Documents/SystemsPharmaWPSorger2011.pdf
Are you interested in receiving updates and participating in SIG discussions? Join the ISoP QSP SIG today, click here. You can also participate in the QSP discussion forum at http://discuss.go-isop.org/c/systems-pharmacology
For additional information regarding the QSP SIG, please visit our google site: https://sites.google.com/view/isopqspsig/home